Replacement Heart Valves
Sorin Group to manufacture parts of Boston Scientific’s Lotus valve
German court rules for Edwards Lifesciences in patent war over Medtronic’s CoreValve heart valve
Early-stage MitrAssist touts $1M funding for valve-in-valve device
Early-stage MitrAssist whizzed by it’s hoped-for raise of $600,000, landing $1 million from angel and private investors in support of the company’s mitral valve implant.
Claret Medical raises $3.6M through private offering
Updated July 8, 2013, at 5:30 a.m. company updates. The funds were raised through a private offering of convertible promissory notes.
California-based medical device maker Claret Medical has raised $3.6 million so far through a private offering, company officials confirmed with MassDevice.com.
Middle Peak raises $8.5M for mitral valve implant
Middle Peak Medical said it raised an $8.5 million Series A round to develop its technology for mitral valve replacement.
The Palo Alto, Calif.- and Munich-based medical device company said the round was co-led by Wellington Partners and Seventure Partners, joined by prior backer High-Tech Gründerfonds Management.
Middle Peak said it will keep its research & development operations in Palo Alto and establish clinical and regulatory operations in Europe.
Edwards Lifesciences wins Japanese approval for next-gen Sapien XT heart valve
Edwards Lifesciences (NYSE:EW) won the green light from Japanese regulators for its Sapien XT transcatheter aortic heart valve system, the 1st device of its kind to hit the shelves in the island-nation.
Edwards Lifesciences’ Perimount heart valve fares well in 25-year study
The Perimount aortic valve implant made by Edwards Lifesciences (NYSE:EW) lasts about 17 years post-implantation, according to 25-year data from a study of the valve in patients younger than 60.
Medtronic notches small win in German TAVI war with Edwards Lifesciences
Edwards Lifesciences comes back down to earth – hard
Investors shrug off FDA warning letter for Edwards
Investors seemed unfazed by news of a warning letter from the FDA for Edwards Lifesciences (NYSE:EW) over a Utah cardiac surgery systems plant.